ClinicalTrials.gg
RecruitingNCT05564091CATALYSTUpdated Apr 18, 2025

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

An interventional study of Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device and Cataract surgery in Primary Open Angle Glaucoma, sponsored by Nova Eye, Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Nova Eye, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Glaucoma, Open-Angle with a site in Germany — 7 open to participants now, 11 under way, none of them phase 3. Glaucoma, Open-Angle · Germany.

Planned enrollment
22nd of 46
78 · median 60
Started
2022
with 2 others
No phase
22 of 64
5 open now
Primary completion
2027-06
later than 5 of 10 live
Registered
57th of 64
by date
Lead sponsor
2 of 64
Nova Eye, Inc.

Among the 64 studies in Glaucoma, Open-Angle with a site in Germany, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2022, is one of 22 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 57th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 64 studies in Glaucoma, Open-Angle with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Glaucoma, Open-Angle with a site in Germany, or all of them as a file.
02

Study summary

A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

Keywords

  • Canaloplasty
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate, primary open angle glaucoma
  • Characteristics consistent with mild to moderate glaucoma
  • Use of 1 - 4 ocular hypotensive medications at the Screening exam and meets the IOP (intraocular pressure) criteria
  • Visually significant cataract

Exclusion criteria

Exclusion Criteria:

Any of the following prior treatments for glaucoma (study eye):

  • Laser Trabeculoplasty
  • Endocyclophotocoagulation (ECP) or Micropulse laser
  • iStent or iStent Inject
  • Hydrus Microstent
  • Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma drainage device/valve.
  • Prior canaloplasty (ab-interno and ab-externo)
  • Prior goniotomy, or trabeculotomy (ab-interno or ab-externo)
  • Suprachoroidal stent (e.g., Cypass, iStent Supra, XEN, MINIject)
  • Concurrent IOP-lowering procedure other than use of the iTrackTM Advance canaloplasty device at the time of surgery (e.g., ECP, CPC, etc.)
  • Previous treatment with iTrack (Note: permitted if fellow eye only was treated)
  • Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Cataract surgery combined with ab-interno canaloplasty

    Ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.)

    Device: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device

  • Other
    Control: Cataract surgery

    Cataract surgery alone

    Procedure: Cataract surgery

Interventions

  • DeviceCataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device

    360 degree microcatheterization and viscodilation of Schlemm's canal

  • ProcedureCataract surgery

    Cataract surgery alone

    Also known as: Phacoemulsification

06

What researchers measure

Primary outcomes

  1. Reduction in mean Intraocular Pressure (IOP) at 12 months compared to baseline

    IOP will be measured at each study visit using Goldmann applanation tonometry

    Time frame: 12 months

  2. Reduction in number of glaucoma medications at 12 months compared to baseline

    The number of glaucoma medications will be recorded at 12 months compared to baseline

    Time frame: 12 months

Secondary outcomes

  1. Reduction in mean Intraocular Pressure (IOP) at 24-months compared to baseline

    IOP will be measured at each study visit using Goldmann applanation tonometry

    Time frame: 24 months

  2. Reduction in glaucoma medications at 24-months compared to baseline

    The number of glaucoma medications will be recorded at 24-months compared to baseline

    Time frame: 24 months

07

Study locations

4 of 4 sites recruiting
  • Berkeley Eye Center
    Sugar Land, Texas 77478, United States
    Recruiting
    • Morgan Micheletti, MD · Contact
  • University of Bonn Eye Clinic
    Bonn, Germany
    Recruiting
    • Karl Mercieca, MD · Contact
  • St. Johannes Hospital
    Dortmund, Germany
    Recruiting
    • Markus Kohlhaas, MD · Contact
  • Augencentrum Köln Ophthalmology
    Köln, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.

Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 57 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartActual
Sep 8, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564091
Lead sponsor
Nova Eye, Inc.
Collaborators
Nova Eye Medical GmbH
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Sep 8, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 18, 2025

Study contacts

Mike Pickrel
Contact
MPickrel@Nova-Eye.com
800-391-2316
Norbert Koerber, MD
principal investigator · Augencentrum Köln Ophthalmology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion